Dentons Lee’s Bernard K. Ham participates as a panelist in Bio NewCo strategy session at BIX 2026

Bernard K. Ham, Senior Attorney at Dentons Lee, participated as a panelist in the session titled "NewCo Is No Longer an Option: Practical Strategies for Bio NewCo" at BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), held at COEX in Seoul on October 29.

The session brought together leading experts from the biotechnology and investment sectors to explore the growing role of the NewCo model in helping Korean biotech companies expand globally. Bernard joined Jaejun Lee, CEO of Ildong Pharmaceutical, Seulki Lee, CEO of D&D Pharmatech, and Joshua Resnick, Partner at RA Capital, for an engaging discussion on NewCo strategies and opportunities.

Drawing on his extensive experience advising on cross-border transactions, Bernard shared practical insights into the benefits of the NewCo model and key considerations for successful transactions. He emphasized that technology transfer and equity investment agreements should be negotiated together in NewCo transactions, highlighting the importance of carefully evaluating investors' drug development capabilities and financial resources, as well as the scope of technology transfers and equity-related rights.

Bernard also highlighted the need for greater awareness and understanding of the NewCo model in Korea, noting its potential to create new growth opportunities for Korean biotech companies and support the global commercialization of innovative technologies.

Dentons Lee remains committed to supporting innovation and growth in the biotechnology, pharmaceutical and life sciences sectors by leveraging its legal experience and Dentons' extensive global network.

Related Articles

• Newsis | Key Considerations for Biotech Companies Exploring NewCo Strategies
• Dailypharm | "Less Than 10% of Technology Licensing Milestones Actually Received"…Why the NewCo Model Is Gaining Attention

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com